Recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the prevention of invasive fungal infection due to filamentous fungi;Recomendaciones sobre la prevención de la infección fúngica invasora por hongos filamentosos de la Sociedad Española Enfermedades Infecciosas y Microbiología Clínica (SEIMC)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 3, 2010, Pages

  Ruiz Camps, Isabel ^a   Aguado, Jose María ^b   Almirante, Benito ^a   Bouza, Emilio ^c   Ferrer Barbera, Carmen ^a   Len, Oscar ^a   López Cerero, Lorena ^d   Rodríguez Tudela, Juan Luis ^e   Ruiz, Miguel ^f   Solé, Amparo ^g   Vallejo, Carlos ^h   Vázquez, Lourdes ⁱ   Zaragoza, Rafael ^j   Cuenca Estrella, Manuel ^e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f TELSTAR Project SA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL UNIVERSITARIO DR PESET   (Spain)

more..

Author keywords

Antifungal prophylaxis; Aspergillus; Conidia counting; Prevention measures

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; FLUCONAZOLE; GAMMA INTERFERON; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POSACONAZOLE; PREDNISONE; STEROID; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; AIR CONDITIONING; AIR MONITORING; AMBIENT AIR; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANNABIS SMOKING; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; CHRONIC GRANULOMATOUS DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLONY FORMING UNIT; CONIDIUM; CONTAMINATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; FEEDING; FUNGAL COLONIZATION; FUNGAL DETECTION; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INSTRUMENT STERILIZATION; INVASIVE CANDIDIASIS; LAW; LIVER CIRRHOSIS; LUNG TRANSPLANTATION; MASK; MEDICAL SOCIETY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PROPHYLAXIS; PROTECTIVE CLOTHING; RECOMMENDED DRUG DOSE; REVIEW; ROOM VENTILATION; SANITATION; SCEDOSPORIUM; SMOKING; TEMPERATURE; TREATMENT DURATION;

EID: 77950627673     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.11.007     Document Type: Article

References (170)

1. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310-50.
2. Gavalda J, Mellado E. Aspergilosis. En: Ausina V, Moreno S, editores. Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Madrid: Editorial Mé-dica Panamericana, 2006. p. 637-46.
3. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68:1941-62.
4. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
5. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006;173:707-17.
6. Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45:1161-70.
7. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173-80.
8. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345-51.
9. Jantunen E, Nihtinen A, Anttila VJ. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2008;10: 156-61.
10. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-66.
11. Martino R, Subira M, Rovira M, Solano C, Vázquez L, Sanz GF, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116:475-82.
12. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-59.
13. Fortun J, Martin-Davila P, Moreno S, De Vicente E, Nuno J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065-70.
14. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005;41:52-9.
15. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis. 2003;3:156-61.
16. Winkelstein JA, Marino MC, Johnston Jr RB, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155-69.
17. Gallin JI, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc. 2007;118:175-85.
18. Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect. 2005;11:427-9.
19. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782-800.
20. Bulpa PA, Dive AM, Garrino MG, Delos MA, González MR, Evrard PA, et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med. 2001;27:59-67.
21. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43:577-84.
22. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis. 1998;26:1473-5.
23. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621-5.
24. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003;15:71-5.
25. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Álvarez-Lerma F, Nolla-Salas J, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005;9:R191-9.
26. Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG, Huijgens PC. Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med. 1996;22:1315-22.
27. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO. Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care. 2006;21:322-7.
28. Meersseman W, Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med. 2007;33:1679-81.
29. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27-34.
30. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269-76.
31. El Hamamsy I, Durrleman N, Stevens LM, Perrault LP, Carrier M. Aspergillus endocarditis after cardiac surgery. Ann Thorac Surg. 2005;80:359-64.
32. Pasqualotto AC, Denning DW. Post-operative aspergillosis. Clin Microbiol Infect. 2006;12:1060-76.
33. Dimopoulos G, Piagnerelli M, Berre J, Salmon I, Vincent JL. Post mortem examination in the intensive care unit: still useful? Intensive Care Med. 2004;30:2080-5.
34. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205-16.
35. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006;10:R31.
36. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-75.
37. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5:609-22.
38. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139:519-31.
39. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824-33.
40. Anaissie EJ, Stratton SL, Dignani MC, Summerbell RC, Rex JH, Monson TP, et al. Pathogenic Aspergillus species recovered from a hospital water system: A 3-year prospective study. Clin Infect Dis. 2002; 34:780-9.
41. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment-rethinking our approach to prevention. Clin Infect Dis. 2001;33:1549-52.
42. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982;116:430-7.
43. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006;63:246-54.
44. Guinea J, Pelaez T, Alcala L, Bouza E. Outdoor environmental levels of Aspergillus spp. conidia over a wide geographical area. Medical Mycology. 2006;44:349-56.
45. Morris G, Kokki MH, Anderson K, Richardson MD. Sampling of Aspergillus spores in air. J Hosp Infect. 2000;44:81-92.
46. Shelton BG, Kirkland KH, Flanders WD, Morris GK. Profiles of airborne fungi in buildings and outdoor environments in the United States. Appl Environ Microbiol. 2002;68:1743-53.
47. Bouza E, Pelaez T, Pérez-Molina J, Marín M, Alcala L, Padilla B, et al. Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air. J Hosp Infect. 2002;52:234-42.
48. Noskin GA, Peterson LR. Engineering infection control through facility design. Emerg Infect Dis. 2001;7:354-7.
49. Falvey DG, Streifel AJ. Ten-year air sample analysis of Aspergillus prevalence in a university hospital. J Hosp Infect. 2007;67:35-41.
50. ISO 14644-4.2001. Salas limpias y locales anexos controlados. Diseño, construcción y puesta en servicio. Anexo A (informativo). Conceptos de control y separación. 2001.
51. ISO 14644-1.1999. Salas limpias y locales anexos. Clasificación de la limpieza del aire. 1999.
52. UNE 100713:2005. Instalaciones de acondicionamiento de aire en hospitales. 2005.
53. Commision Directive 2003/94/EC. EC Guide to good manufacturing practice (EC GMP). Annex 1: Manufacture of sterile medicinal products. 11-1-2003.
54. Faure O, Fricker-Hidalgo H, Lebeau B, Mallaret MR, Arnbroise-Thomas P, Grillot R. Eight-year surveillance of environmental fungal contamination in hospital operating rooms and haematological units. J Hosp Infect. 2002; 50:155-60.
55. Nihtinen A, Anttila VJ, Richardson M, Meri T, Volin L, Ruutu T. The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant. 2007;40:457-60.
56. Rupp ME, Iwen PC, Tyner LK, Marion N, Reed E, Anderson JR. Routine sampling of air for fungi does not predict risk of invasive aspergillosis in immunocompromised patients. J Hosp Infect. 2008;68:270-1.
57. Dykewicz CA. Hospital infection control in hematopoietic stem cell transplant recipients. Emerg Infect Dis. 2001;7:263-7.
58. Sehulster L, Chinn RYW. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-10).
59. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499-511.
60. Harvey IM, Leadbeatter S, Peters TJ, Mullins J, Philpot CM, Salaman JR. An outbreak of disseminated aspergillosis associated with an intensive care unit. Community Med. 1988;10:306-13.
61. Krasinski K, Holzman RS, Hanna B, Greco MA, Graff M, Bhogal M. Nosocomial fungal infection during hospital renovation. Infect Control. 1985;6(7):278-82.
62. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol. 1989;5: 131-42.
63. Anderson K, Morris G, Kennedy H, Croall J, Michie J, Richardson MD, et al. Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air. Thorax. 1996;51:256-61.
64. Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect. 1994;26(1):27-35.
65. Kennedy HF, Michie JR, Richardson MD. Air sampling for aspergillus spp. during building activity in a paediatric hospital ward. J Hosp Infect. 1995;31:322-5.
66. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect. 1991;18(Suppl A):466-72.
67. Nesa D, Lortholary J, Bouakline A, Bordes M, Chandenier J, Derouin F, et al. Comparative performance of impactor air samplers for quantification of fungal contamination. J Hosp Infect. 2001;47:149-55.
68. Grupo de Trabajo de la Sociedad Española de Medicina Preventiva SPeHyeI. Recomendaciones para la vigilancia, prevención y control de infecciones en hospitales en obras. http://www.mpsp.org/mpsp/Documentos/Otros/ hos-o bras.htm. 2000.
69. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Mahfouz TH, Rex JH, et al. Cleaning patient shower facilities: A novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis. 2002;35:E86-8.
70. Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med. 2002;162:1483-92.
71. Tovey ER, Green BJ. Measuring environmental fungal exposure. Med Mycol. 2005;43(Suppl 1):S67-70.
72. Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Müller FMC, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: A new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871-8.
73. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101:2542-6.
74. Warris A, Gaustad P, Meis JFGM, Voss A, Verweij PE, Abrahamsen TG. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect. 2001;47:143-8.
75. Warris A, Voss A, Abrahamsen TG, Verweij PE. Contamination of Hospital Water with Aspergillus fumigatus and Other Molds. Clin Infect Dis. 2002;34:1159-60.
76. Warris A, Klaassen CHW, Meis JFGM, de Ruiter MT, de Valk HA, Abrahamsen TG, et al. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clinl Microbiol. 2003;41:4101-6.
77. MMWR. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recomendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and marrow Transplantation. 49 (No. RR-10), 1-147. 2000.
78. Health Canada. Construction-related nosocomial infections in patients in health care facilities. Decreasing the risk of Aspergillus, Legionella and other infections. http://hc-sc.gc.ca. 2001.
79. MMWR. Guidelines for environmental infection control in health-care facilities. 52 (No. RR-10), 1-44. 2003.
80. Dodek P, Keenan S, Cook D, Heyland D, Jacka M, Hand L, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med. 2004;141:305-13.
81. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson Jr RH. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis. 1983;148:230-8.
82. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med. 1993;153:2010-6.
83. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol. 1991;9:77-84.
84. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999;78:123-38.
85. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-66.
86. Wingard JR, Beals SU, Santos GW, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant. 1987;2: 175-81.
87. Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-9.
88. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev. 2008:CD007394.
89. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised de.nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46: 1813-21.
90. Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone marrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant. 1995;15:469-73.
91. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. NCI Monogr. 1990:43-5.
92. Lee LD, Berkheiser M, Jiang Y, Hackett B, Hachem RY, Chemaly RF, et al. Risk of bioaerosol contamination with Aspergillus species before and after cleaning in rooms filtered with high-efficiency particulate air filters that house patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2007;28: 1066-70.
93. Panagopoulou P, Filioti J, Petrikkos G, Giakouppi P, Anatoliotaki M, Farmaki E, et al. Environmental surveillance of .lamentous fungi in three tertiary care hospitals in Greece. J Hosp Infect. 2002;52:185-91.
94. Perdelli F, Sartini M, Spagnolo AM, Dallera M, Lombardi R, Cristina ML. A problem of hospital hygiene: the presence of aspergilli in hospital wards with different air-conditioning features. Am J Infect Control. 2006;34:264-8.
95. Sautour M, Sixt N, Dalle F, L'ollivier C, Calinon C, Fourquenet V, et al. Prospective survey of indoor fungal contamination in hospital during a period of building construction. J Hosp Infect. 2007;67:367-73.
96. Curtis L, Cali S, Conroy L, Baker K, Ou CH, Hershow R, et al. Aspergillus surveillance project at a large tertiary-care hospital. J Hosp Infect. 2005;59:188-96.
97. Alberti C, Bouakline A, Ribaud P, Lacroix C, Rousselot P, Leblanc T, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect. 2001;48: 198-206.
98. Arnow PM, Sadigh M, Costas C, Weil D, Chudy R. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis. 1991;164:998-1002.
99. Weems Jr JJ, Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control. 1987;8:71-5.
100. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a twenty-year period. Infect Control Hosp Epidemiol. 1989;10:299-305.
101. Weber SF, Peacock Jr JE, Do KA, Cruz JM, Powell BL, Capizzi RL. Interaction of granulocytopenia and construction activity as risk factors for nosocomial invasive filamentous fungal disease in patients with hematologic disorders. Infect Control Hosp Epidemiol. 1990;11:235-42.
102. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect. 1989;14:89-94.
103. Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, Coureul MH, et al. Efficacy of prevention by high-effciency particulate air filtration or laminar air flow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20:508-13.
104. Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect. 2004;56:93-100.
105. Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987;83:709-18.
106. Withington S, Chambers ST, Beard ME, Inder A, Allen JR, Ikram RB, et al. Invasive aspergillosis in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration. J Hosp Infect. 1998;38: 11-8.
107. Benet T, Nicolle MC, Thiebaut A, Piens MA, Nicolini FE, Thomas X, et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis. 2007;45:682-6.
108. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis. 2001;33:1546-8.
109. Grant S, Olsen CW. Preventing zoonotic diseases in immunocompromised persons: the role of physicians and veterinarians. Emerg Infect Dis. 1999;5:159-63.
110. Johnson RA, Meadows RL. Older Latinos, pets, and health. West J Nurs Res. 2002;24:609-20.
111. Parslow RA, Jorm AF, Christensen H, Rodgers B, Jacomb P. Pet ownership and health in older adults: findings from a survey of 2,551 community-based Australians aged 60-64. Gerontology. 2005;51:40-7.
112. Robertson ID, Irwin PJ, Lymbery AJ, Thompson RC. The role of companion animals in the emergence of parasitic zoonoses. Int J Parasitol. 2000;30:1369-77.
113. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230-46.
114. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51.
115. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055-61.
116. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28:331-40.
117. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of .uconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-52.
118. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495-503.
119. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer. 2000;89:1611-25.
120. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl 1):S49-58.
121. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33:139-44.
122. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999;23:163-8.
123. Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12:235-40.
124. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol. 2006;17:1306-12.
125. Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med. 1994;97:509-14.
126. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:577-82.
127. Leather HL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev. 2006;20:267-87.
128. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46:1401-8.
129. Ficha técnica o resumen de las características del producto Mycamine. http:// www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/emea- combinedh734es. pdf. 2008.
130. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-16.
131. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615-26.
132. Jarque I, Romero M, Heras I, Fernández-Sevilla A, Tormo M, Hernández D, et al. Effectiveness of itraconazole as prophylaxis of invasive fungal infection (IFI) in neutropenic patients with haematological malignancies. Washington: American Society for Microbiology; 2008. [Comunicación M-2181].
133. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527-33.
134. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705-13.
135. European Leukemia Net. Antifungal prophylaxis. European Conference on Infections in Leukemia. http://www.leukemia-net.org/content/treat-re search/supportive-care/standards-sop/e4702/infoboxContent5849/ECIL2-An tifungalprophylaxis.pdf. 2007.
136. National Comprehensive Cance Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. http:// www.nccn.org/JNCCN/toc/2008feb.asp. The Journal of the National Comprehensive Cancer Network 6. 2008.
137. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.
138. Ficha técnica o resumen de las características del producto Canadiol. https:// sinaem4.agemed.es/consaem/especialidad.do?metodo=verFicha WordPdf&codigo=61864&formato=pdf&formulario=FICHAS. 2003.
139. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-47.
140. Ficha técnica o resumen de las características del producto Noxa.l. http:// www.emea.europa.eu/humandocs/PDFs/EPAR/noxa.l/H-610-PI-es.pdf. 2005.
141. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol. 2007;78:275-82.
142. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601-14.
143. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect. 2002;51:288-96.
144. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258-66.
145. Sole A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med. 2009;15:243-53.
146. Ballard J, Edelman L, Saffle J, Sheridan R, Kagan R, Bracco D, et al. Positive fungal cultures in burn patients: a multicenter review. J Burn Care Res. 2008;29:213-21.
147. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.
148. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711-6.
149. Monforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant. 2001;20:1274-81.
150. Monforte V, Ussetti P, Lopez R, Gavalda J, Bravo C, de Pablo A, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28:170-5.
151. Palmer SM, Drew RH, Whitehouse JD, Tapson VF, Davis RD, McConnell RR, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72:545-8.
152. Gavalda J, Roman A. Infection in lung transplantation. Enferm Infecc Microbiol Clin. 2007;25:639-49.
153. Borro JM, Sole A, De La TM, Pastor A, Fernandez R, Saura A, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40:3090-3.
154. Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008-16.
155. Tolman JA, Nelson NA, Son YJ, Bosselmann S, Wiederhold NP, Peters JI, et al. Characterization and Pharmacokinetic Analysis of Aerosolized Aqueous Voriconazole Solution. Eur J Pharm Biopharm. 2009.
156. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation. 1995;59:45-50.
157. Fortun J, Martin-Davila P, Moreno S, Barcena R, De Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003;52:813-9.
158. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy.
159. Singhal S, Ellis RW, Jones SG, Miller SJ, Fisher NC, Hastings JG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl. 2000;6:588-95.
160. Hellinger WC, Bonatti H, Yao JD, Álvarez S, Brumble LM, Keating MR, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl. 2005;11:656-62.
161. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. 2002;74:688-95.
162. Muñoz P, Rodríguez C, Bouza E, Palomo J, Yánez JF, Domínguez MJ, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4:636-43.
163. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348:2416-22.
164. Fortun J, Martin-Davila P, Montejo M, Muñoz P, Cisneros JM, Ramos A, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87:424-35.
165. American Society of Transplantament. Fungal infections. Am J Transplant. 2004;4(Suppl 10):110-34.
166. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
167. Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009.
168. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-11.
169. Vallejo C. Terapeútica de la infección fúngica. Haematologica. 2003;87(Supl. 6):53-62.
170. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother. 2008;42:1859-64.